Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Walsh

Vascular Surgery Mason City, IA Medical Doctor

NPI 1225458144 CMS profile 1285882

250 S Crescent Dr, Mason City, IA 50401

Open in the dashboard

General payments

$12,991

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Walsh of Mason City, IA is reported in the CMS Open Payments database as having received $12,991 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $477 15
2024 General $3,220 29
2023 General $495 17
2022 General $1,289 18
2021 General $2,258 12
2020 General $2,720 10
2019 General $2,533 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Walsh
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kenneth Walsh were reported at $477. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kenneth Walsh Vascular Surgery median Middle half National median
2019 $2,533 $796 $226–$2,363 $163
2020 $2,720 $348 $118–$1,110 $114
2021 $2,258 $471 $158–$1,421 $132
2022 $1,289 $725 $222–$2,183 $149
2023 $495 $836 $257–$2,440 $160
2024 $3,220 $909 $252–$2,619 $164
2025 $477 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $4,949 7 payments
  2. Penumbra, Inc. $2,456 10 payments
  3. Medtronic, Inc. $2,194 28 payments
  4. Nippon Boehringer Ingelheim Co., Ltd. $1,230 1 payment
  5. Cook Medical LLC $439 9 payments
  6. Endologix, Inc. $413 7 payments
  7. Shockwave Medical, Inc $216 5 payments
  8. Philips Electronics North America Corporation $200 2 payments
  9. Bard Peripheral Vascular, Inc. $125 1 payment
  10. W. L. Gore & Associates, Inc. $115 2 payments
  11. Other $655 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $4,203 3 payments
  2. Food and Beverage $4,196 84 payments
  3. Travel and Lodging $2,658 14 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,230 1 payment
  5. Education $705 2 payments
Products named General payments · program years 2019–2025
  1. Endurant Aortic Stent Grafts $4,244 5 payments
  2. RUBY Coil $1,868 5 payments
  3. VENASEAL EndoVenous Therapies $994 15 payments
  4. VenaSeal EndoVenous Therapies $627 4 payments
  5. Indigo System $588 5 payments
  6. Zenith Spiral-Z $223 3 payments
  7. Endurant Aortic Stent Grafts $205 3 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $200 4 payments
  9. Alto Abdominal Stent Graft System $165 3 payments
  10. AFX2 Bifurcated Endograft System $159 3 payments
  11. Other $1,731 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

101

Median for Vascular Surgery: 122

Drug cost

$38,546

Median for Vascular Surgery: $14,135

Branded share of claims

86.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $23,405
Xarelto Rivaroxaban Brand 15 $14,782
Clopidogrel Clopidogrel Bisulfate Brand 27 $230
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 18 $106
Tramadol Hcl Generic 14 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$104,228

Medicare's payments for the services billed

Medicare patients

316

Average age 74

Services billed

836

155 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Chronic kidney disease 60%
Arthritis 55%
Ischemic heart disease 53%
Heart failure 46%
Atrial fibrillation 32%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record